Teratogenic Risk of Statins in Pregnancy
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the teratogenic potential of statins in women of child-bearing age. Data Sources: A PubMed search (1980-September 2012) was performed using the search terms statin and pregnancy, then repealed using statin and teratogenicity. Results were limited to articles published in English reporting on use of statins in humans. Study Selection and Data Extraction: All articles presenting data on pregnancy outcomes after statin use during any trimester of pregnancy were included. Three case reports, 2 case series, 2 systematic reviews, 2 registry-based studies, and 1 prospective observational cohort study were reviewed. Data Synthesis: Since initial premarketing studies of lovastatin in animals, terato-genesis has been assumed to be a classwide function of statins' mechanism of action. Data from human exposure during pregnancy have been gathered and analyzed in a variety of study formats to formulate useable conclusions on statins' actual teratogenic risk and pattern of associated birth defects. Although the current trend is that actual risk is lower than once thought, the available literature is limited by potential reporting bias, contains overlap in the data, and frequently lacks numbers of total exposures to statins during pregnancy with reported malformations. Additionally, no human studies included data on the 2 newest statins (rosuvastatin, pitavastatin); the more lipophilic statins (lovastatin, simvastatin) have the most experience and thus have more evidence related to teratogenic potential. Conclusions: Human teratogenic risk has not been proven nor has it been ruled out by the available data on statin use in pregnancy. Possible differences in risk between individual statins require further evaluation. Additional data, including prospective observational cohorts with inadvertent maternal exposure to statins during early weeks of gestation, should further help to clarify appropriate recommendations for statin use in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
Edison, R. J., & Muenke, M. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30386 · Cited by 206
Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes
Taguchi, N., Rubin, E. T., Hosokawa, A., Choi, J., Ying, A. Y., Moretti, M. E., Koren, G., & Ito, S. (2008) · Reproductive Toxicology · doi:10.1016/j.reprotox.2008.06.009 · Cited by 142
Motherisk Rounds: Risks of Statin Use During Pregnancy: A Systematic Review
Kazmin, A., Garcia-Bournissen, F., & Koren, G. (2007) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)32656-1 · Cited by 117
Pregnancy Outcomes in Familial Hypercholesterolemia: A Registry-Based Study
Toleikyte, I., Retterstøl, K., Leren, T. P., & Iversen, P. O. (2011) · Circulation · doi:10.1161/circulationaha.110.990929 · Cited by 112
Cited by
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy
Regitz-Zagrosek, V., Roos-Hesselink, J. W., Bauersachs, J., Blomström-Lundqvist, C., Cífková, R., De Bonis, M., Iung, B., Johnson, M. R., Kintscher, U., Kranke, P., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy340 · Cited by 2,292
ESC Guidelines on the management of cardiovascular diseases during pregnancy
Endorsed by the European Society of Gynecology (ESG), T. A. F. E. P. C. (., Authors/Task Force Members, Regitz-Zagrosek, V., Blomstrom Lundqvist, C., Borghi, C., Cifkova, R., Ferreira, R., Foidart, J.-M., Gibbs, J. S. R., Gohlke-Baerwolf, C., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr218 · Cited by 1,924
Use of Medication for Cardiovascular Disease During Pregnancy
Halpern, D. G., Weinberg, C. R., Pinnelas, R., Mehta-Lee, S., Economy, K. E., & Valente, A. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.075 · Cited by 309
Statins and congenital malformations: cohort study
Bateman, B. T., Hernandez-Diaz, S., Fischer, M. A., Seely, E. W., Ecker, J. L., Franklin, J. M., Desai, R. J., Allen-Coleman, C., Mogun, H., Avorn, J., et al. (2015) · BMJ · doi:10.1136/bmj.h1035 · Cited by 236
The risks of statin use in pregnancy: a systematic review
Karalis, D. G., Hill, A. N., Clifton, S., & Wild, R. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.07.002 · Cited by 175
Metadata
- Authors
- Godfrey, L. M., Erramouspe, J., & Cleveland, K. W.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2012-10
- Volume
- 46
- Issue
- 10
- Pages
- 1419-1424
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2118700954
- Cited by
- 65
- References
- 5
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.